...
首页> 外文期刊>Vaccine >Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720
【24h】

Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720

机译:Seppic ISA 720中配制的促红细胞生成前疟疾候选疫苗ICC-1132的安全性,免疫原性和功效

获取原文
获取原文并翻译 | 示例
           

摘要

ICC-1132, a recombinant virus-like particle comprising of a modified hepatitis B core protein with a B cell (NANP) and two T cell epitopes of Plasmodium falciparum circumsporozoite protein (CSP), was administered i.m. as a single 50 microg dose in Seppic ISA 720 to 11 volunteers. Local reactogenicity and systemic side effects were acceptable with the predominant finding being mild pain at the injection site. This regimen induced anti-NANP antibodies in 10/11 and modest T cell responses. There was no evidence of protection from experimental challenge with P. falciparum sporozoites. Other formulations and/or multi-dose regimens will be required to enhance the immunogenicity and efficacy of ICC-1132.
机译:ICC-1132是一种重组病毒样颗粒,它由带有B细胞(NANP)和恶性疟原虫环子孢子蛋白(CSP)的两个T细胞表位的修饰的乙型肝炎核心蛋白组成。在Seppic ISA 720中以50微克的单剂量给予11位志愿者。局部反应原性和全身性副作用是可以接受的,主要发现是注射部位的轻度疼痛。该方案在10/11和适度的T细胞应答中诱导抗NANP抗体。没有证据表明恶性疟原虫子孢子具有免受实验攻击的保护作用。需要其他制剂和/或多剂量方案来增强ICC-1132的免疫原性和功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号